Form 8-K · Current Report · Filed 2024-06-24
Illumina Completes GRAIL Spin-Off
On June 24, 2024, Illumina, Inc. completed the previously announced spin-off of GRAIL, Inc. to its shareholders. Illumina shareholders received one share of GRAIL for every six shares of Illumina, with Illumina retaining a 14.5% stake in GRAIL. GRAIL began trading under the ticker symbol 'GRAL' on June 25, 2024. The spin-off involved several agreements, including a Separation and Distribution Agreement, a Tax Matters Agreement, and an Employee Matters Agreement. Further financial and strategic details will be provided in a future investor update.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001193125-24-167025
- CIK
- 0001110803
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Completion of Acquisition or Disposition of Assets
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$105.61
Next session
+4.0%
Since filing
+94.2%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Exhibits (6)
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.